OKYO Pharma Limited
OKYO · Healthcare · $63M
$1.69+3.05%
Price
$1.58
$2.00
Apr 28, 26Jul 29, 26
Quarterly Financials
RevenueOperating IncomeNet Income
3/'27
Revenue$0M
Operating Income—
Net Income—
6/'26 vs prev quarter
TSMC reports record June revenue, second quarter sales top guidanceJul 13
OKYO Pharma advances toward Phase 3 FDA trial - ICYMIJul 11
OKYO Pharma advances toward Phase 3 FDA trial - ICYMIJul 11
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal painJul 8
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal PainJul 8
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology SymposiumJul 7
